Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases (2019 - 2025)

Historic Current Leases for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $2.3 million.

  • Fulcrum Therapeutics' Current Leases rose 1002.81% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 1002.81%. This contributed to the annual value of $2.2 million for FY2024, which is 27.37% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Current Leases stood at $2.3 million, which was up 1002.81% from $2.3 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Current Leases high stood at $2.7 million for Q1 2023, and its period low was $469000.0 during Q1 2021.
  • For the 5-year period, Fulcrum Therapeutics' Current Leases averaged around $1.9 million, with its median value being $2.2 million (2025).
  • Per our database at Business Quant, Fulcrum Therapeutics' Current Leases surged by 45479.74% in 2022 and then plummeted by 2369.51% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Current Leases (Quarter) stood at $469000.0 in 2021, then surged by 454.8% to $2.6 million in 2022, then dropped by 15.76% to $2.2 million in 2023, then dropped by 0.27% to $2.2 million in 2024, then rose by 7.41% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.3 million for Q2 2025, and $2.2 million during Q1 2025.